Updated Efficacy Data from Ph 1/2 Transtar102 Trial of Osemitamab + Nivolumab and CAPOX in 1L G/GEJ Cancer Presented
“We are encouraged to see the continued strength of the clinical signals in this study, which reinforce the potential of osemitamab to deliver meaningful benefit to patients in need of more effective treatment options,” said Dr. Charlie Qi, Executive Vice President, Head of Global Clinical Development at Transcenta. “Further, these updated data continue to demonstrate that the combination of osemitamab with nivolumab and CAPOX is safe and well tolerated as a first-line regimen for patients with advanced G/GEJ cancer.”
Share:
More News
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.
“Many solid tumors remain difficult to treat despite advances in immunotherapy,” said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. “Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents.”
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the first patient has been dosed in a Phase III clinical trial evaluating its novel Nectin-4-targeting ADC (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).